[PPT] - Achieving h APP iness on your mobile device mHealth apps for EDs PowerPoint Presentation

SLIDE 1

mHealth apps for EDs

Kirsty Short, Advanced Trainee in Emergency Medicine (ECI)

Achieving hAPPiness on your mobile device

SLIDE 2

SLIDE 3

Apps for Clinicians

SLIDE 4

Improving Patient Experience

Translation apps
Procedure explanations
Departmental ipads

SLIDE 5

Ac

I

NSW Agency

for Clinical

lnnovat1

n

~

Emergency

~

Care Tnstitute

SLIDE 6

Ac

I

NSW Agency

for Clinical

lnnovat1

n

~

Emergency

~

Care Tnstitute

SLIDE 7

Piedmont-based companies develop medical apps to improve patient care | MyFOX8.com - News, Weather, Sports and more from WGHP Fox 8 Television

SLIDE 8

ee

SLIDE 9

SLIDE 10

!I

1 ncr-·d oed o~

ic

Li c. S

~ art

)

~-~-

~

Emergency

~

Care Institute

SLIDE 11

Algorithms Calendar

IJ.\

Courses

•••() Optus 4G

9:23 93% I

I

Advanud Lift 5upfH1rl

:h

..

lngChlld

1 ~
I!

Paediatric Basic Life Support Paediatric Advanced Life Support Cardiac Arrest Management The Choking Child Anaphylaxis Management

SLIDE 12

•••:J Optus 4G

9:23 93% I

I•

·1

I

~

·

. ...

!I •

IBI

1!111!11

SVT (Supra-Ventricular Tachycardia) Managem ... VT (Ventricular Tachycardia) Managem ... Decreased Conscious Level Management Status Epilepticus Cervical Spine Management

•••o Optus 4G

9:24 93% I

I

a

pis

Condder pre-hospital m edlcatJons

Status Epilepticus

20mln Rapid Sequence Induction with Thiopentone or Propofol

SLIDE 13

Ac

I

NSW Agency for Clinical lnnovat1on

~

Emergency

~

Care Tnstitute

SLIDE 14

SLIDE 15 1Pad 9

7:41 am 98% - "

CT Scan

Discussion

Case 10: Appendicitis This patient also has appendicitis. No contrast is seen within the appendix despite excellent filling of the cecum. There is subtle but definite adjacent stranding in the

mesentery. The mucosa enhances more than in other parts of the bowel. There is

thickening of the cecum at the base of the appendix. This case is less obvious than Case 9, but the findings are still there. If you did not immediately find the appendix, "run" the colon again. Here is the ileocecal valve. The proximal ascending colon is situated superiorly. The cecum is then inferior and the appendix originates from the same side of the cecum as the ileocecal valve. See schematic. Once you find the appendix you must decide if it is normal. If the appendix is filled with air or contrast filled it is normal. This is the most useful finding because it virtually excludes appendicitis. Appendicitis is caused by obstruction of the appendix and an

bstructed appendix does not fill with air or oral contrast. Occasionally, a small amount
f air can remain present in the tip of the appendix because it has become trapped by

the inflammation. This is uncommon. Contrast should never be seen only in the tip (how could it get there if the lumen is obstructed?). The mucosa enhances secondary to hyperemia: inflammed bowel becomes hyperemic. Mesenteric stranding is related to inflammation in the surrounding fat. Thickening of the cecal tip is secondary to the inflammation in the adjacent appendix. There are times where the CT findings are indeterminate. For example, what if the appendix is air or contrast filled but measures 8 mm (greater than 6 mm). What if the appendix will not fill with contrast, measures only 5 mm, and is neither hyperemic nor surrounded by fat stranding? What if you cannot find the appendix? If there are mixed signs use clinical signs and symptoms and discuss the case with the surgeon. Watching and waiting is appropriate in many subsets of patients.

SLIDE 16 1 ad ";"' :41 am % _ ..

CT Scan

Discussion

Return to discussion.

SLIDE 17

Ac

I

NSW Agency

for Clmical

Innovation

~

Emergency

~

Care Institute

SLIDE 18

iPad 9 7:35am

*

100% -

0. Search

Categories A

A -a 0 2 Gradient and Ratio

~

v

)?:

Alveolo-arterial oxygen gradient and ratio Abbreviated Burn Severity Index Anesthesiology Cardiology Diabetes Outcome of burn injuries A BC D2 Score Risk of stroke after TIA A BC D3- I Score

~

l£

Risk of stroke after TIA

A

ABG Analyzer Blood gas interpretation

B

ER -ICU Electrolytes Evidence-Based Alvarado Score c Medicine Diagnostic score for appendicitis

D

Anion Gap (Serum)

E

Diagnosis of metabolic acidosis

F

~

~ ~

Anion Gap (Urine)

G

Source of bicarbonate loss

H

Gastrointestinal Infectious Disease Neurology A PACH E II Severity of disease in the ICU

K

APGAR

L

Newborn initial assessment

~

!}

A

M

ASA Classification Assessment of risk before surgery

N

AVPU Scale Nurses Obstetrics Oncology Assessment of level of consciousness

p

B

a

Basal Energy Expenditure

R

Harris-Benedict formula s

llt\

fU

Basal Metabolic Rate

T

Mifflin-St Jeor formula

u Behavioral Pain Scale Pediatrics Pulmonary Renal

v Assessing pain in noncommunicative patient

w Bicarbonate Deficit

Estimation of bicarbonate loss

&

Blatchford Score

.

Risk assessment for upper Gl bleeding

Body Surface Area Trauma

Several formulas for BSA assessment Burn Area (rule of nines) Quick assessment of burned area

c

(j)

<>-

1> -

1> -

Patients Formulas Cate ories

SLIDE 19

iPad 9 7:36am

X

ABCD2 Score Diabetes ID Hypertension - Age 2: 60 years - Clinical Features Unilateral Symptom Duration 1 0 - 59 min Similar Stroke Risk ABCD3-I Score

Score 6 high risk

Cardiovascular Risk (ACC/AHA) CHADS2 Score CHA2DS2-VASc Score Stroke Diagnosis Aphasia Classification Cincinnati Prehosp. Stroke Scale ROSIER Scale Disability Barthel Index Glasgow Outcome Scale Modified Rankin Scale NIH Stroke Scale

> > > > > > > > > > > >

*

100% -

CD

SLIDE 20

Ac

I

NSW Agency for Clmical lnnovatton

~

Emergency

~

Care Institute

SLIDE 21

Search Browse

Brand Name

>

Generic Name

>

MIMS Therapeutic Class

>

Action and Indications

>

Company

>

*

000

SLIDE 22

Search Browse

Q Enter the name of a drug to search for Cadati n 5/20 Tablets

Amlodipine - Atorvastatin

Cadati n 5/40 Tablets

Amlodipine - Atorvastatin

Cadati n 5/80 Tablets

Amlodipine - Atorvastatin

Caduet 10/1 0 Tablets

Amlodipine - Atorvastatin

Caduet 10/20 Tablets

Amlodipine - Atorvastatin

Caduet 10/40 Tablets

Amlodipine - Atorvastatin

Caduet 10/80 Tablets

SLIDE 23

Reset Pill Identifier Search Shape

Any >

Color

Any >

Scoring

Any >

Form

Any >

Class of Drug

Any >

Company

Any >

*

000

SLIDE 24

Ac

I

NSW Agency

for Clinical

lnnovat1

n

~

Emergency

~

Care Tnstitute

SLIDE 25

iPad 9

ABCs Abdominai/GI Cardiovascular Dermatology ENT Environmental Heme/One Infectious Disease Neurology OB/GYN Orthopedics Pediatrics Pulmonary Procedures Psych Radiology

Gate o

"'

"

Pedi Tape

7:37am

palm EM

Q.

Search

*

100% -

CD

Jv.-

1:?

Meds Favorites

SLIDE 26

iPad 9 7:36am

*

100% -

Back Pediatric Rashes

rn

Age: 3-12y, nonimmune adults
Season: Winter/Spring
Prodrome: Nonspecific fever and malaise
Morphology: Macular Erythema on face, erythematous macular eruption for first week followed by

lacy erythema

Distribution: Face followed by extremities; lacy rash over extensor surfaces
Associations: Aplastic crisis; hydrops fetalis; papularpurpuric socks syndrome

HAND-FOOT-MOUTH DISEASE (COXSACKIEVIRUS A-16)

Age:< 10y, occasionally older
Season: Summer/Early Fall
Prodrome: Fever, anorexia, sore throat
Morphology: Small vesicles or red papules; ulcerations in mouth
Distribution: Hand, foot, mouth, tongue, tonsils
Associations: Dehydration, ferbile seizures, herpangina

SLIDE 27 t::$1 am

l

1U '¥o

~

Pedi Tape

3 kg (6.6 lbs)

Newborn: 18-20 inches (46-52 em)

4 kg (8.8 lbs)

1 month old: 20-22 inches (52-57 em)

5 kg

(11 .0 lbs)

2 month old: 22-24 inches (57-61 em)

6 kg (13.0 lbs)

3 month old: 24-25 inches (61-64 em)

7 kg (15.4 lbs)

4 month old: 25-27 inches (64-68 em)

8 kg (17 .6 lbs)

6 month old: 27-28 inches (68-71 em)

9 kg (19.8 lbs)

9 month old: 28-30 inches (72-75 em)

1 0 kg (22.0 lbs)

1 year old: 30-31 inches (75-80 em)

11 kg (24.3 lbs)

1 year, 3 month old: 31-33 inches (80-85 em)

12 kg (26.5 lbs)

1 year, 6 month old: 33-35 inches (85-90 em)

13 kg (28. 7 lbs)

2 year old: 35-37 inches (90-94 em)

14 kg (30.9 lbs)

2 year, 4 month old: 37-39 inches (94-98 em)

15 kg (33.1 lbs)

2 year, 7 month old: 39-40 inches (98-1 02 em)

16 kg (35.3 lbs)

3 year old: 40-41 inches (102-104 em)

17 kg (37 .5 lbs)

3 year, 4 month old: 41-42 inches (1 05-108 em)

18 kg (39. 7 lbs)

3 year, 7 month old: 42-43 inches (1 08-110 em)

19 kg (41.9 lbs)

4 year old: 43-45 inches (11 0-114 em)

20 kg (44.1 lbs)

4 year, 4 month old: 45-46 inches (114-117 em)

a

..&. u

At- *

Category Pedi Tape Search Meds Favorites

SLIDE 28

Ac

I

NSW Agency

for Clinical

lnnovat1

n

~

Emergency

~

Care Tnstitute

SLIDE 29

Links

ECI Apps Page: http://www.ecinsw.com.au/ed-applications SMACC talk: http://intensivecarenetwork.com/723-smacc-tessa-davis- how-to-create-a-medical-app/ App development: iclinicalapps.com

SLIDE 30

)

·f A

ustralian Government

• OC!IIIr!\mcnt of

Heulth 11nd Ageing Therapeutic Goods Administralio11

Australian regulatory guidelines for medical devices (ARGMD)

Part 1-lntroduction

Version 1.1 , May 2011

TrAHcaJth

s.~fery

I \,:1.

Regulation

I

Contains Nonbinding Recor mnendotious

Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff

Document issued on: September 25, 2013 T he draft ofthis guidance was issued on J uly 21, 2011. For questions regarding this document, contact Bakul Patel at 301-796-5528 or by electronic mail at BalrulPatel@fda . .

bhs.

gov . For questions regarding this document concerning devices regulated by CBER, contact the Office of Cormnunication, Outreach and Development (OCOD), by calling 1-800-835-4709

r 301-827-1800

.

~

ETR

.

S. Department of Heal!b and Human Senic.

es Food and Dmg Administration CentH for De\ice

s and Radiological Health

Centfl' for Biologics El·aluation and Research

1 -

SLIDE 31

Therapeutics Goods Act 1989: ‘Medical device’

Any instrument/apparatus/material intended to be used for human beings for:

Dx, prevention, monitoring, treatment or alleviation of disease
Dx, monitoring, treatment, alleviation/compensation for injury or disability
Does not achieve its principle intended action in or on the human body by

pharmacological, immunological or metabolic means